• Create Account
  • Sign In
  • My account
    Orders Downloads Address Payment methods Account details
  • SUBSCRIBE
  • SEARCH
MY ACCOUNT
  • Create Account
  • Sign In
  • My account
    Orders Downloads Address Payment methods Account details
  • SUBSCRIBE
  • SEARCH
Action Another action Something else here
X All Individual Users: You may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at webadmin@psychiatrist.com. 
logo
  • CME
  • JOURNALS
        • Journals
          • The Journal of Clinical Psychiatry
          • JCP Weekly
          • JCP Archives
          • The Primary Care Companion for CNS Disorders
          • PCC Weekly
          • PCC Archives
  • TOPICS
        • Topics
          • Addiction
          • Anxiety
          • Assessment
          • Anxiolytics
          • Bipolar
          • Complementary
          • COVID-19
          • Cultural
          • Cross Cultural Psychiatry
          • Delivery
          • Depression
          • Delivery Of Care
          • Dermatology
          • Electroconvulsive Therapy
          • End Of Life Palliative Care
          • Gastroenterology
          • See all Topics
  • AUTHORS/REVIEWERS
    • Reprints and Permissions
    • Information for Authors (PCC)
    • Submit a PCC Paper
    • Information for Authors (JCP)
    • Submit a JCP Paper
    • Information for Reviewers
  • RESOURCES
    • Media Relations
    • Information for Advertisers
    • CNS Job Market
    • FAQ
Action Another action Something else here
X All Individual Users: You may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at webadmin@psychiatrist.com. 

Body Dysmorphic Disorder

Showing all 9 results

    LETTERS TO THE EDITOR

    Olfactory Reference Syndrome as a Subtype of Body Dysmorphic Disorder

    Read commentary on the study about Olfactory Reference Syndrome and how it can be a potential subtype of Body Dysmorphic Disorder.

    Angélica M. Prazeres & more
    ORIGINAL ARTICLES

    Effectiveness of Pharmacotherapy for Body Dysmorphic Disorder: A Chart-Review Study

    Katharine A. Phillips & more
    ORIGINAL ARTICLES

    Effectiveness of Pharmacotherapy for Body Dysmorphic Disorder: A Chart-Review Study

    Katharine A. Phillips & more
    ORIGINAL ARTICLES

    Prevalence and Clinical Features of Body Dysmorphic Disorder in Adolescent and Adult Psychiatric Inpatients

    Jon E. Grant and Scott J. Crow
    LETTERS TO THE EDITOR

    Successful Treatment of Nondelusional Body Dysmorphic Disorder With Olanzapine: A Case Report

    Jon E. Grant
    LETTERS TO THE EDITOR

    Fatal Body Dysmorphic Disorder by Proxy

    Naureen Atiullah and Katharine A. Phillips
    LETTERS TO THE EDITOR

    Fatal Body Dysmorphic Disorder by Proxy

    Naureen Atiullah and Katharine A. Phillips
    ORIGINAL ARTICLES

    Delusionality and Response to Open-Label Fluvoxamine in Body Dysmorphic Disorder

    Katharine A. Phillips & more
    LETTERS TO THE EDITOR

    Body Dysmorphic Disorder by Proxy

    Stephen C. Josephson and Eric Hollander

MOST POPULAR
ORIGINAL RESEARCH

Serum Fatty Acid Latent Classes Are Associated With Suicide in a Large Military Personnel Sample

Levels of several fatty acids (FAs) have been linked to suicidal behavior, though research...

Arthur Thomas Ryan & more
ORIGINAL RESEARCH

Cross-Cutting Symptom Domains Predict Functioning in Psychotic Disorders

Read this study to learn how both psychotic and nonpsychotic symptom domains predict funct...

Julia M. Longenecker & more
META-ANALYSIS

Single Versus Multiple Daily Dosing Regimens of Psychotropic Drugs for Psychiatric Disorders: A Systematic Review and Meta-Analysis

Single-daily-dose regimens are easier for patients to follow than multiple-dose regimens a...

Yuhei Kikuchi & more

Sign-up to stay
up-to-date today!

Already registered? Sign In

© Copyright 2021

Physicians Postgraduate Press, Inc.
Lifelong Learning for Clinicians

  • JCP ISSN: Online 1555-2101, Print 0160-6689
  • PCC ISSN: Online 2155-7780, Print 2155-7772
  • MedFair.com US Patent No. 684794
  • Contact Us
  • Customer Service
  • FAQ
  • About Psychiatrist.com
  • Call for Papers
  • Information for Authors (PCC)
  • Information for Authors (JCP)
  • Reprints and Permissions
  • Media
  • Advertisers
  • CNS Job Market
  • Privacy Policy
  • Unsubscribe from Elerts
  • Terms of Use
Search Articles
Action Another action Something else here
click
Hello Pop
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1 First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2). Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
Related Articles
Table Of Contents